Keystone Investors PTE Ltd. Takes Position in Icon Plc $ICLR

Keystone Investors PTE Ltd. bought a new stake in Icon Plc (NASDAQ:ICLR) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 33,526 shares of the medical research company’s stock, valued at approximately $5,867,000.

A number of other large investors have also added to or reduced their stakes in ICLR. Private Trust Co. NA lifted its holdings in Icon by 200.0% in the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after buying an additional 94 shares in the last quarter. Wilmington Savings Fund Society FSB lifted its stake in shares of Icon by 153.4% in the third quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after acquiring an additional 201 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in Icon in the second quarter valued at about $61,000. Pilgrim Partners Asia Pte Ltd purchased a new position in Icon in the third quarter valued at about $63,000. Finally, Geneos Wealth Management Inc. grew its stake in Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ICLR has been the topic of a number of recent analyst reports. Robert W. Baird set a $119.00 target price on Icon in a research report on Friday, February 13th. Bank of America reiterated an “underperform” rating and set a $75.00 price objective on shares of Icon in a research note on Thursday, February 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Icon in a research report on Monday, December 29th. Truist Financial restated a “hold” rating and issued a $222.00 target price (down from $231.00) on shares of Icon in a research note on Thursday, January 8th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $105.00 price target on shares of Icon in a research note on Thursday, February 12th. Six analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Icon currently has a consensus rating of “Hold” and an average target price of $157.47.

Icon Trading Up 1.9%

NASDAQ ICLR opened at $108.14 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. Icon Plc has a one year low of $66.57 and a one year high of $211.00. The company has a 50-day simple moving average of $159.45 and a 200-day simple moving average of $170.33. The firm has a market capitalization of $8.73 billion, a PE ratio of 14.63, a price-to-earnings-growth ratio of 2.72 and a beta of 1.27.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.